Serum Anti-Cardiolipin IgG Test at Chughtai Lab

Serum Anti-Cardiolipin IgG at Chughtai Lab

The Serum Anti-Cardiolipin IgG test is a highly specialized immunological assay utilized to detect and quantify immunoglobulin G (IgG) autoantibodies directed against cardiolipin. Cardiolipin is a key phospholipid component of the inner mitochondrial membrane, playing a critical role in maintaining mitochondrial structure and cellular energy production. When the body’s immune system mistakenly identifies cardiolipin or its associated plasma proteins—specifically beta-2-glycoprotein I—as foreign, it produces anti-cardiolipin antibodies (aCL). The presence of these autoantibodies is a primary hallmark of Antiphospholipid Syndrome (APS), an autoimmune disorder characterized by recurrent arterial or venous thrombosis and obstetric complications such as unexplained pregnancy loss.

At Chughtai Lab, this test is performed using advanced Enzyme-Linked Immunosorbent Assay (ELISA) or chemiluminescent immunoassay (CLIA) technology. These state-of-the-art methodologies ensure high sensitivity and specificity, allowing for the precise measurement of IgG titers expressed in GPL units (standardized IgG anti-cardiolipin units). Evaluating the IgG isotype is clinically vital, as high titers of IgG are more strongly correlated with thromboembolic events and adverse pregnancy outcomes than other isotypes like IgM or IgA. By measuring these levels, clinicians can assess a patient's risk for hypercoagulability, guide long-term anticoagulation therapy, and investigate the underlying causes of recurrent miscarriages or systemic autoimmune diseases like Systemic Lupus Erythematosus (SLE).

Clinical Procedure: What to Expect

Patient Preparation

To ensure the highest level of diagnostic accuracy and prevent pre-analytical errors, patients undergoing the Serum Anti-Cardiolipin IgG test at Chughtai Lab should follow these preparation guidelines:

• No Fasting Required: Fasting is generally not necessary for this specific immunological test. Patients can eat and drink normally prior to sample collection.
• Medication Review: It is essential to inform your prescribing physician and the laboratory staff of all medications you are currently taking. Anticoagulants (such as heparin, warfarin, or direct oral anticoagulants), antiplatelet drugs, and immunosuppressive therapies can influence clinical interpretation, though they do not directly interfere with the ELISA assay itself.
• Infection Status: If you have recently had an acute viral, bacterial, or parasitic infection, inform your doctor. Transient anti-cardiolipin antibodies can temporarily appear during or immediately after infections, potentially leading to false-positive results.
• Hydration: Staying well-hydrated is recommended as it makes venipuncture easier and reduces the risk of vasovagal episodes during blood collection.

During the Procedure

The collection of the blood sample is a routine, safe, and efficient process conducted by highly trained phlebotomists at Chughtai Lab:

• Patient Positioning: The patient is comfortably seated in a specialized phlebotomy chair. The phlebotomist will ask the patient to extend their arm and rest it on a stable surface.
• Site Selection and Preparation: The phlebotomist identifies a suitable vein, typically the median cubital vein in the antecubital fossa (the crook of the elbow). The skin over the selected vein is thoroughly cleansed with an antiseptic swab (usually 70% isopropyl alcohol) to prevent contamination.
• Venipuncture: A sterile, single-use needle attached to a vacuum collection tube (typically a gold-top serum separator tube or a red-top clot activator tube) is gently inserted into the vein. Patients may feel a brief, mild pinch or sting.
• Sample Collection: The required volume of blood (approximately 3 to 5 mL) is drawn into the tube. Once the collection is complete, the needle is withdrawn, and a sterile cotton ball or gauze is applied to the puncture site with gentle pressure to promote hemostasis.
• Post-Procedure Care: An adhesive bandage is placed over the site. The entire venipuncture process takes less than five minutes. The collected blood is then allowed to clot, centrifuged to separate the serum, and transported under strict temperature-controlled conditions to the immunology department for analysis.

When is a Serum Anti-Cardiolipin IgG Test Performed?

Unexplained Blood Clots (Thrombosis)

Physicians frequently order the Serum Anti-Cardiolipin IgG test when a patient presents with unexplained venous or arterial thrombotic events. This includes deep vein thrombosis (DVT) in the lower extremities, pulmonary embolism (PE), or premature arterial thromboses leading to stroke or myocardial infarction in young individuals without traditional cardiovascular risk factors. Identifying the presence of IgG antibodies helps determine if an underlying autoimmune hypercoagulable state is responsible for the clotting, which directly influences the duration and intensity of subsequent anticoagulant therapy.

Recurrent Pregnancy Loss and Obstetric Complications

This test is a critical component of the diagnostic workup for women experiencing recurrent pregnancy loss, defined as two or more consecutive, unexplained miscarriages before the 10th week of gestation. It is also indicated in cases of a single unexplained fetal death of a morphologically normal fetus at or beyond the 10th week of gestation, or premature birth before the 34th week due to severe pre-eclampsia, eclampsia, or placental insufficiency. Anti-cardiolipin antibodies can cause placental thrombosis and inflammation, leading to compromised fetal-maternal circulation.

Evaluation of Systemic Lupus Erythematosus (SLE)

In patients diagnosed with or suspected of having Systemic Lupus Erythematosus (SLE), the Serum Anti-Cardiolipin IgG test is routinely performed. Approximately 30% to 40% of patients with SLE test positive for anti-cardiolipin antibodies. Testing helps clinicians stratify the patient's risk for secondary Antiphospholipid Syndrome, allowing for proactive monitoring and preventive strategies against potential thrombotic complications or organ damage associated with lupus-induced vasculopathy.

Investigation of Prolonged Clotting Times (aPTT)

When routine coagulation screening reveals an unexplained prolongation of the Activated Partial Thromboplastin Time (aPTT) that does not correct upon mixing studies, further investigation is required. Although anti-cardiolipin antibodies are associated with increased clotting in vivo, they can interfere with phospholipid reagents used in in vitro coagulation assays, causing a paradoxical prolongation of clotting times. This test helps clarify whether the prolonged aPTT is linked to antiphospholipid autoimmunity.

Diagnosis of Antiphospholipid Syndrome (APS)

The definitive diagnosis of Antiphospholipid Syndrome requires both clinical criteria (thrombosis or pregnancy morbidity) and laboratory confirmation. The Serum Anti-Cardiolipin IgG test is one of the three standard laboratory assays used for this purpose, alongside the Lupus Anticoagulant and Anti-Beta-2-Glycoprotein I antibody tests. To satisfy the international consensus criteria (Sydney criteria), a positive IgG result must be confirmed on a second sample collected at least 12 weeks after the initial positive test to rule out transient, infection-induced antibodies.

What Does a Serum Anti-Cardiolipin IgG Test Detect?

The Serum Anti-Cardiolipin IgG test is designed to detect and quantify specific autoantibodies that can indicate several clinical states, including:

• Clinically Significant Autoimmunity: High titers of IgG antibodies (typically greater than 40 GPL units) strongly indicate primary or secondary Antiphospholipid Syndrome.
• Low-to-Moderate Antibody Levels: Low-positive results (15 to 40 GPL units) may suggest early-stage autoimmune activity, resolving transient antibodies, or borderline clinical significance.
• Transient Positivity: Temporary elevations of IgG antibodies caused by recent viral infections (such as hepatitis, HIV, cytomegalovirus, or Epstein-Barr virus) or bacterial infections (such as syphilis or tuberculosis).
• Drug-Induced Antibodies: Elevated levels secondary to the use of certain medications, including chlorpromazine, procainamide, quinidine, or phenytoin, which usually resolve after drug discontinuation.
• Secondary Antiphospholipid Syndrome: The presence of these antibodies in association with established connective tissue disorders, most notably Systemic Lupus Erythematosus (SLE) or rheumatoid arthritis.
• Increased Risk of Venous Thromboembolism: High levels correlate with a significantly elevated risk of deep vein thrombosis (DVT) and pulmonary embolism.
• Arterial Thrombosis Risk: Association with an increased risk of ischemic stroke, transient ischemic attacks (TIAs), and myocardial infarction.
• Microvascular Thrombosis Risk: Potential for small vessel occlusions that can lead to organ damage, including renal microangiopathy or cutaneous lesions like livedo reticularis.
• Placental Insufficiency: Detection of antibodies that target trophoblast cells, leading to impaired implantation, placental infarction, and restricted fetal growth.
• Thrombocytopenia: An association with low platelet counts, as anti-cardiolipin antibodies can bind to platelets, leading to their premature clearance by the spleen.
• Neurological Manifestations: Association with non-thrombotic neurological symptoms such as chorea, transverse myelitis, or cognitive dysfunction in patients with high antibody titers.
• Catastrophic Antiphospholipid Syndrome (CAPS) Risk: In rare cases, extremely high titers in a critically ill patient can point toward CAPS, characterized by widespread microvascular thrombosis and multi-organ failure.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is committed to delivering highly accurate diagnostic results with optimal turnaround times. Because the Serum Anti-Cardiolipin IgG test is a specialized immunological assay requiring precise ELISA or CLIA processing, the analysis is conducted by dedicated laboratory professionals under strict quality control protocols. Typically, the final verified report is available within 24 to 48 hours from the time of sample collection.

Patients can access their diagnostic reports seamlessly through Chughtai Lab's advanced digital ecosystem. Once the report is finalized and signed off by a consultant pathologist, an automated SMS notification containing a secure download link is sent to the patient's registered mobile number. Reports can also be viewed, downloaded, and archived via the official Chughtai Lab mobile application or the patient portal on the Chughtai Lab website. For added convenience, physical copies of the reports can be collected from any Chughtai Lab diagnostic center or home delivery can be arranged. Each report features a secure QR code to allow healthcare providers to verify the authenticity of the diagnostic findings instantly.

Serum Anti-Cardiolipin IgG Findings Overview

The following table outlines the parameters evaluated during the Serum Anti-Cardiolipin IgG test, along with typical normal and abnormal clinical findings:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Anti-Cardiolipin IgG Concentration	< 15 GPL units (Negative)	>= 15 GPL units (Positive; categorized as low, moderate, or high positive)
Thrombotic Risk Stratification	No increased risk of thrombosis	Elevated risk of venous thromboembolism (DVT, PE) or arterial occlusion (stroke, MI)
Obstetric Risk Profile	Normal pregnancy outcomes expected (in relation to antiphospholipid antibodies)	Increased risk of recurrent early miscarriage, late-term fetal loss, or severe pre-eclampsia
Autoimmune Association	No evidence of antiphospholipid-related autoimmune activity	Strong association with primary Antiphospholipid Syndrome (APS) or secondary APS (e.g., in SLE)
Coagulation Correlation	Normal baseline coagulation parameters	May correlate with prolonged aPTT or presence of Lupus Anticoagulant
Platelet Count Correlation	Normal platelet count (150,000 – 450,000 /mcL)	Thrombocytopenia (low platelet count) due to antibody-mediated platelet destruction
Temporal Persistence (12-Week Interval)	Antibodies absent or transient (resolved upon retesting)	Persistent positive titers confirmed after 12 weeks, fulfilling laboratory criteria for APS

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Serum Anti-Cardiolipin IgG?

• Accredited and Quality-Controlled Laboratories: Chughtai Lab operates under strict international quality standards, participating in external quality assurance programs to ensure maximum accuracy.
• Advanced Immunodiagnostic Technology: The lab utilizes state-of-the-art ELISA and automated chemiluminescent platforms for highly sensitive antibody detection.
• Expert Pathologists and Immunologists: All specialized tests are supervised and interpreted by experienced consultant pathologists and clinical immunologists.
• Convenient Home Sample Collection: Patients can schedule a professional phlebotomist to collect blood samples in the comfort of their homes across Pakistan.
• Extensive Nationwide Network: With hundreds of collection centers and main labs across major cities, Chughtai Lab offers unmatched accessibility.
• Secure and Instant Digital Reports: Patients can access their records anytime via the Chughtai Lab mobile app, website portal, or SMS links.
• Strict Cold Chain Management: Samples are transported under precise temperature-controlled conditions to preserve the integrity of serum proteins.
• Patient-Centric Care: Chughtai Lab is dedicated to providing a comfortable, professional, and compassionate environment for all diagnostic needs.